Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy

NCT04535609 is registered in ClinicalTrials.gov with Reneo Pharma Ltd as lead sponsor.

NCT NCT04535609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04535609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 24 Weeks Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
Lead sponsor
Reneo Pharma Ltd
Phase
Phase 2
Overall status
Completed
Start date
May 21, 2021
Completion date
October 5, 2023
Enrollment
213 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

primary mitochondrial myopathy